Zhou Y, Wang D-L, Pang Q
Shandong University, Jinan, Shandong, P.R. China.
Eur Rev Med Pharmacol Sci. 2016 Jul;20(14):3035-9.
Long non-coding RNAs (lncRNAs) are emerging as biomarkers and as important regulators of the biological processes and tumorigenesis in cancer. The purpose of this study is to investigate the clinical significance of lncRNA SPRY4-IT1 in glioma.
The expression level of SPRY4-IT1 was examined by the quantitative Real-time PCR (qRT-PCR) in glioma tissues and control tissues and its association with overall survival of patients was analyzed by statistical analysis. Survival curves were made using the Kaplan-Meier method, and the log-rank test was used to analyze the differences between clinicopathological characteristics and survival in glioma patients.
The expression level of SPRY4-IT1 was significantly higher in glioma in comparison to normal matched tissue (p < 0.01). Furthermore, lncRNA SPRY4-IT1 was associated significantly with WHO grade (p = 0.009) and tumor size (p = 0.003). A significant difference was found that glioma patients with high SPRY4-IT1 expression level had distinctly shorter OS than patients with low SPRY4-IT1 expression level. Furthermore, Multivariate analysis indicated SPRY4-IT1 as an independent prognostic indicator for glioma patients (p = 0.003), CONCLUSIONS: The lncRNA SPRY4-IT1 may be a potential prognostic bio¬marker of glioma.
长链非编码RNA（lncRNAs）正逐渐成为生物标志物以及癌症生物学过程和肿瘤发生的重要调节因子。本研究旨在探讨lncRNA SPRY4-IT1在胶质瘤中的临床意义。
采用定量实时荧光定量PCR（qRT-PCR）检测胶质瘤组织和对照组织中SPRY4-IT1的表达水平，并通过统计学分析分析其与患者总生存期的关系。采用Kaplan-Meier法绘制生存曲线，采用对数秩检验分析胶质瘤患者临床病理特征与生存率之间的差异。
与正常匹配组织相比，胶质瘤中SPRY4-IT1的表达水平显著更高（p < 0.01）。此外，lncRNA SPRY4-IT1与世界卫生组织（WHO）分级（p = 0.009）和肿瘤大小（p = 0.003）显著相关。发现SPRY4-IT1表达水平高的胶质瘤患者的总生存期明显短于SPRY4-IT1表达水平低的患者。此外，多因素分析表明SPRY4-IT1是胶质瘤患者的独立预后指标（p = 0.003）。结论：lncRNA SPRY4-IT1可能是胶质瘤潜在的预后生物标志物。
